Collagen type IV alpha 3-4-5 network (α3α4α5(IV) network)

The Collagen IV α3α4α5 network is a specialized extracellular matrix structure essential for the integrity and selective filtration function of the glomerular basement membrane (GBM) in the kidney. Composed of α3, α4, and α5 chains encoded by the COL4A3, COL4A4, and COL4A5 genes, this heterotrimeric network replaces the developmental α1α1α2 network during glomerular maturation to provide superior mechanical stability. Mutations in these genes lead to Alport syndrome, a progressive hereditary nephritis characterized by GBM lamellation, proteinuria, and eventual renal failure, often accompanied by sensorineural hearing loss and ocular defects. Additionally, the non-collagenous (NC1) domain of the α3 chain is the primary autoantigen in Goodpasture syndrome (anti-GBM disease), where pathogenic autoantibodies trigger rapidly progressive glomerulonephritis. Therapeutic approaches include standard-of-care RAAS inhibitors and SGLT2 inhibitors to reduce mechanical stress on the membrane, while emerging strategies focus on gene therapy to restore the network. Other experimental treatments include chemical chaperones like 4-phenylbutyric acid to improve mutant protein folding and anti-microRNA therapies to mitigate secondary fibrosis. In the context of autoimmune disease, treatment involves plasmapheresis and immunosuppression to remove or prevent the production of antibodies targeting this network.

Other names

α3α4α5(IV) collagenCollagen IV alpha 3-4-5 heterotrimerGoodpasture antigenGBM collagen IV networkCOL4A3/4/5 network

Restoration of the structural network through gene or mRNA therapy; stabilization of mutant collagen folding via chemical chaperones; reduction of intraglomerular pressure and proteinuria via RAAS and SGLT2 inhibition; and removal or suppression of autoantibodies in autoimmune disease.